Observational studyScientific reports2025
Early detection of mesenteric ischemia in critically ill patients following cardiac surgery.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intestinal fatty acid-binding protein (I-FABP) at ICU admission as early biomarker of intestinal injury and predictor of mortality in septic shock.Intensive care medicine experimental · 2026Article
- Relationship between hypercoagulability and mesenteric ischemia early after cardiac surgery.Journal of thrombosis and thrombolysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenteric ischemia (Me-Is) is a severe complication with high mortality after cardiac surgery. We examined whether intestinal fatty acid binding protein (I-FABP) might serve as a biomarker for early detection of Me-Is following cardiac surgery. Between March 2022 and December 2023, we conducted a prospective observational study of 500 consecutive patients undergoing cardiac surgery with cardiopulmonary bypass. Blood samples were obtained at five time points perioperatively. An immunoassay was used to determine I-FABP levels in 48 individuals at high risk of Me-Is due to lactic acidosis > 4 mmol/L and interleukin (IL)-6 > 600 pg/mL: 6 patients with confirmed Me-Is (cMe-Is), 18 patients with suspected Me-Is (sMe-Is), and 24 patients a in propensity score-matched control group. Of the 48 patients, 62.5% initially had mild gastrointestinal dysfunction (AGI ≤ II), but 80% of them progressed to AGI III or higher, with 25% reaching AGI IV. Baseline serum I-FABP values were similar between the three groups. The six patients with cMe-Is showed significantly elevated serum I-FABP levels from ICU admission to 36 h post-admission, peaking at 207,411.46 pg/mL. ROC analysis identified serum I-FABP as the most accurate predictor of Me-Is, with an AUC of 0.973 at 36 h post-ICU admission (95% CI [0.764-0.997], p < 0.001) and an optimal cut-off of > 1421 pg/mL, with 100% sensitivity. In contrast, IL-6 and lactate levels showed no significant differences between groups. Serum I-FABP showed high accuracy in predicting Me-Is after cardiac surgery, outperforming IL-6 and lactate. Our data suggest that I-FABP may have value as a biomarker for early detection of Me-Is after cardiac surgery and help to improve patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.